The latest news about premature ejaculation

The latest news about premature ejaculation

April 16,  2010 The latest news about premature ejaculation has come in from Europe:  PRNewswire’s   “Men slow to talk about fast sex”.    It cites data from a new survey on PE, which confirmed something that we sex therapists have always known:   Premature ejaculation is a serious matter that adversely affects millions of men’s lives, and the lives of their partners. The study being reported evidently surveyed thousands of men and women to reach this important conclusion. But it wasn’t really news at all to anyone familiar with PE. What was news was that the study was sponsored by a pharmaceutical company:   Janssen-Cilag, together apparently with several European patient support groups. Janssen-Cilag,  a part of the  Johnson & Johnson family of companies, has since February 2009  been winning approval for its new premature ejaculation drug, dapoxetine (marketed in Europe as Priligy), in countries in Europe and around the world, but not yet in the United States. I’m a  fan of this drug, even though since I’m  a physician and sex therapist practicing in the United States I can’t yet prescribe it.  I was a medical advisor to Johnson & Johnson in 2005, when the company attempted unsuccessfully to gain FDA approval for the drug.  And I sincerely hope that the FDA will someday reconsider dapoxetine and allow the drug to be prescribed by US physicians.   Dapoxetine is conceptually not that new.  It’s a short-acting serotonin reuptake inhibitor (SRI), a member of the Prozac family.  We physicians in sexual medicine have prescribed SRI’s for years for men with prematurity, generally with good results. What’s new is that this is the...